查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869587

壞死性筋膜炎市場規模、佔有率和趨勢分析報告：按類型、治療方法、分銷管道、地區和細分市場預測，2025-2033年

Necrotizing Fasciitis Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

壞死性筋膜炎市場摘要

2024年全球壞死性筋膜炎市場規模估計為10.2724億美元，預計2033年將達到20.9781億美元。

預計2025年至2033年間，該市場將以8.3%的複合年成長率成長。推動市場成長的幾個關鍵因素包括：人們對該疾病的嚴重和快速進展的認知不斷提高，從而增加了對有效治療方法的需求。

醫療技術的進步以及創新抗生素和外科手術的廣泛應用改善了患者的治療效果，進一步推動了市場擴張。壞死性筋膜炎（NF）是嚴重的皮膚和軟組織感染疾病，沿著血流受限的筋膜間隙擴散。在早期，淺表組織通常不受影響，導致診斷和治療延誤。隨著病情進展，可涉及筋膜、筋膜周圍間隙、周圍皮膚、軟組織和肌肉。在美國，此病的年發生率約為每10萬人0.4例，部分地區的發生率甚至低至每10萬人1例。

此外，糖尿病、肥胖和免疫力缺乏功能低下等風險因素的日益普遍也導致了病例數的增加。根據國際糖尿病聯盟預測，到2024年，糖尿病將導致340萬人死亡，相當於每9秒鐘就有一人死於糖尿病。此外，全球有5.89億成年人（20-79歲）患有糖尿病。糖尿病患者人數的不斷成長顯著增加了壞死性筋膜炎的風險，從而推動了對專科護理的需求。此外，醫療機構對早期診斷和治療的日益重視，以及醫療費用支出，都促進了該市場的穩定成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 壞死性筋膜炎市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章 壞死性筋膜炎市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2024 年和 2033 年
  • 類型細分儀表板
  • 市場規模、預測與趨勢分析（按類型，2021-2033 年）
  • I 型（多微生物）
  • Ⅱ型（單菌型）
  • 第三型（氣性壞疽/梭菌性肌肉壞死）

5. 壞死性筋膜炎市場：依療法分類的業務分析

  • 按療法分類的市場佔有率，2024 年和 2033 年
  • 治療細分儀表板
  • 按療法分類的市場規模、預測和趨勢分析，2021-2033年
  • 經驗性廣效抗生素
  • 可附加MRSA（耐甲氧西林金黃色葡萄球菌）感染防治方案
  • 輔助抗毒素用於治療侵襲性A類鏈球菌感染。
  • 針對特定病原體的抗菌治療
  • 用於治療壞死性真菌感染疾病的抗真菌藥物
  • 免疫療法

6. 壞死性筋膜炎市場：按通路分類的業務分析

  • 按分銷管道分類的市場佔有率，2024 年和 2033 年
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析，2021-2033年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 壞死性筋膜炎市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • Pfizer Inc.
    • Merck &Co., Inc.（MSD）
    • Gilead Sciences
    • Astellas Pharma
    • Basilea Pharmaceutica
    • CSL Behring
    • Takeda
    • Grifols
    • Octapharma
    • Hikma Pharmaceuticals
Product Code: GVR-4-68040-771-4

Necrotizing Fasciitis Market Summary

The global necrotizing fasciitis market size was estimated at USD 1,027.24 million in 2024 and is projected to reach USD 2,097.81 million by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.

Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.

In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.

Global Necrotizing Fasciitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Type I (Polymicrobial)
  • Type II (Monomicrobial)
  • Type III (Gas gangrene / clostridial myonecrosis)
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Empiric broad-spectrum antibacterials
  • MRSA-coverage add-ons
  • Antitoxin adjunct for invasive GAS
  • Pathogen-targeted antibacterial regimens
  • Antifungals for necrotizing fungal infections
  • Immunotherapies
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Necrotizing Fasciitis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Necrotizing Fasciitis Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 - 2033 (USD Million)
  • 4.4. Type I (Polymicrobial)
    • 4.4.1. Type I (Polymicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
  • 4.5. Type II (Monomicrobial)
    • 4.5.1. Type II (Monomicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
  • 4.6. Type III (Gas gangrene / clostridial myonecrosis)
    • 4.6.1. Type III (Gas gangrene / clostridial myonecrosis) market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 5. Necrotizing Fasciitis Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Empiric broad-spectrum antibacterials
    • 5.4.1. Empiric broad-spectrum antibacterials market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.5. MRSA-coverage add-ons
    • 5.5.1. MRSA-coverage add-ons market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antitoxin adjunct for invasive GAS
    • 5.6.1. Antitoxin adjunct for invasive GAS market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.7. Pathogen-targeted antibacterial regimens
    • 5.7.1. Pathogen-targeted antibacterial regimens market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.8. Antifungals for necrotizing fungal infections
    • 5.8.1. Antifungals for necrotizing fungal infections market estimates & forecasts, 2021 - 2033 (USD Million)
  • 5.9. Immunotherapies
    • 5.9.1. Immunotherapies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 6. Necrotizing Fasciitis Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
  • 6.6. Online pharmacies
    • 6.6.1. Online pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 7. Necrotizing Fasciitis Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America necrotizing fasciitis market estimates & forecasts, by country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Type disease prevalence
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Reimbursement framework
      • 7.4.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Type disease prevalence
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Reimbursement framework
      • 7.4.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Type disease prevalence
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Reimbursement framework
      • 7.4.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Type disease prevalence
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement framework
      • 7.5.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Type disease prevalence
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement framework
      • 7.5.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Type disease prevalence
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Reimbursement framework
      • 7.5.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Type disease prevalence
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Reimbursement framework
      • 7.5.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Type disease prevalence
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Reimbursement framework
      • 7.5.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Type disease prevalence
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Reimbursement framework
      • 7.5.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Type disease prevalence
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Reimbursement framework
      • 7.5.8.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Type disease prevalence
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Reimbursement framework
      • 7.5.9.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Type disease prevalence
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement framework
      • 7.6.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Type disease prevalence
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement framework
      • 7.6.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Type disease prevalence
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement framework
      • 7.6.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Type disease prevalence
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement framework
      • 7.6.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Type disease prevalence
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement framework
      • 7.6.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Type disease prevalence
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement framework
      • 7.6.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Type disease prevalence
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement framework
      • 7.7.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Type disease prevalence
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement framework
      • 7.7.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Type disease prevalence
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement framework
      • 7.8.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Type disease prevalence
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Reimbursement framework
      • 7.8.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Type disease prevalence
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Reimbursement framework
      • 7.8.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Type disease prevalence
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Reimbursement framework
      • 7.8.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc. (MSD)
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Gilead Sciences
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Astellas Pharma
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Basilea Pharmaceutica
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CSL Behring
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Grifols
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Octapharma
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Hikma Pharmaceuticals
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Necrotizing Fasciitis Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 6 Global Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 North America Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 9 North America Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 10 North America Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 13 U.S. Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 14 Canada Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 16 Canada Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 19 Mexico Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 Europe Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 23 Europe Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 24 UK Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 25 UK Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 26 UK Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 27 Germany Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 29 Germany Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 30 France Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 France Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 32 France Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 33 Italy Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 35 Italy Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 36 Spain Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 38 Spain Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 39 Denmark Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 40 Denmark Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 41 Denmark Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 42 Sweden Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Sweden Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 44 Sweden Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Norway Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 46 Norway Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 47 Norway Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 52 Japan Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 54 Japan Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 55 China Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 56 China Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 57 China Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 58 India Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 India Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 60 India Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61 Australia Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 63 Australia Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 65 South Korea Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 66 South Korea Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 Thailand Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 69 Thailand Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 73 Latin America Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 76 Brazil Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 79 Argentina Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Necrotizing Fasciitis Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 86 South Africa Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 90 UAE Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 92 UAE Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Necrotizing Fasciitis Market, By Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Necrotizing Fasciitis Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Necrotizing Fasciitis Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Necrotizing fasciitis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Necrotizing fasciitis market dynamics
  • Fig. 12 Necrotizing fasciitis market: Porter's five forces analysis
  • Fig. 13 Necrotizing fasciitis market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Type I (Polymicrobial) market, 2021 - 2033 (USD Million)
  • Fig. 16 Type II (Monomicrobial) market, 2021 - 2033 (USD Million)
  • Fig. 17 Type III (Gas gangrene / clostridial myonecrosis) market, 2021 - 2033 (USD Million)
  • Fig. 18 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 19 Empiric broad-spectrum antibacterials market, 2021 - 2033 (USD Million)
  • Fig. 20 MRSA-coverage add-ons market, 2021 - 2033 (USD Million)
  • Fig. 21 Pathogen-targeted antibacterial regimens market, 2021 - 2033 (USD Million)
  • Fig. 22 Antifungals for necrotizing fungal infections market, 2021 - 2033 (USD Million)
  • Fig. 23 Immunotherapies market, 2021 - 2033 (USD Million)
  • Fig. 24 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 25 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 26 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 27 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Necrotizing fasciitis market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA Necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait necrotizing fasciitis market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework